| B | 6-week B | p value | Mean (standard deviation) | d value | |
---|---|---|---|---|---|---|
Week 0 | Week 6 | |||||
Social cognition | ||||||
Primary | ||||||
DANVA – face | 2.33 | 13.98 | 0.381 |  |  | 0.33 |
 Oxytocin |  |  |  | 32.6 (8.8) | 33.5 (6.4) |  |
 Placebo |  |  |  | 39.1 (8.4) | 37.4 (7.4) |  |
DANVA – paralanguage | 1.96 | 11.76 | 0.351 |  |  | 0.38 |
 Oxytocin |  |  |  | 27.8 (5.7) | 30.5 (2.7) |  |
 Placebo |  |  |  | 34.1 (3.0) | 35.2 (4.7) |  |
Secondary | ||||||
RMET | – | 22% | 0.004 |  |  | 1.2 |
 Oxytocin |  |  | 0.002* | 48% (20%) | 61% (24%) |  |
 Placebo |  |  |  | 74% (14%) | 63% (12%) |  |
Social function | ||||||
Primary | ||||||
CGI – improvement – social |  |  | 0.582 |  |  | OR = 3.4 |
 Oxytocin |  |  |  |  | 30% improved |  |
 Placebo |  |  |  |  | 11% improved |  |
Secondary | ||||||
SRS | 0.58 | 3.48 | 0.664 | Â | Â | 0.34 |
 Oxytocin |  |  |  | 92.3 (29.9) | 111.4 (13.5) |  |
 Placebo |  |  |  | 84.5 (23.3) | 96.5 (13.0) |  |
Repetitive behaviors | ||||||
Primary | ||||||
RBS-R higher order | – | 4.57 | 0.301 |  |  | −0.22 |
 Oxytocin |  |  |  | 17.0 (10.6) | 17.7 (16.2) |  |
 Placebo |  |  |  | 20.0 (10.8) | 17.8 (13.3) |  |
RBS-R lower order | – | −2.25 | 0.045 |  |  | 0.64 |
 Oxytocin |  |  | 0.065* | 5.8 (4.6) | 2.4 (2.3) |  |
 Placebo |  |  |  | 4.9 (3.7) | 3.7 (2.6) |  |
Secondary | ||||||
YBOCS | 0.16 | 0.96 | 0.220 | Â | Â | 0.13 |
 Oxytocin |  |  |  | 12.0 (3.9) | 9.4 (2.9) |  |
 Placebo |  |  |  | 10.3 (2.5) | 8.1 (2.5) |  |
Quality of life | ||||||
WOQOL – emotional | – | 9.5% | 0.034 |  |  | 0.84 |
 Oxytocin |  |  | 0.031* | 47.8% (16.3%) | 59.5% (16.0%) |  |
 Placebo |  |  |  | 65.2% (12.3%) | 63.2% (12.3%) |  |